27858503|t|High-throughput sequencing of two populations of extracellular vesicles provides an mRNA signature that can be detected in the circulation of breast cancer patients
27858503|a|Extracellular vesicles (EVs) contain a wide range of RNA types with a reported prevalence of non-coding RNA. To date a comprehensive characterization of the protein coding transcripts in EVs is still lacking. We performed RNA-Sequencing (RNA-Seq) of 2 EV populations and identified a small fraction of transcripts that were expressed at significantly different levels in large oncosomes and exosomes, suggesting they may mediate specialized functions. However, these 2 EV populations exhibited a common mRNA signature that, in comparison to their donor cells, was significantly enriched in mRNAs encoding E2F transcriptional targets and histone proteins. These mRNAs are primarily expressed in the S-phase of the cell cycle, suggesting that they may be packaged into EVs during S-phase. In silico analysis using subcellular compartment transcriptome data from the ENCODE cell line compendium revealed that EV mRNAs originate from a cytoplasmic RNA pool. The EV signature was independently identified in plasma of patients with breast cancer by RNA-Seq. Furthermore, several transcripts differentially expressed in EVs from patients versus controls mirrored differential expression between normal and breast cancer tissues. Altogether, this largest high-throughput profiling of EV mRNA demonstrates that EVs carry tumor-specific alterations and can be interrogated as a source of cancer-derived cargo.
27858503	0	26	High-throughput sequencing	T063	C2936623
27858503	49	71	extracellular vesicles	T026	C3894683
27858503	84	88	mRNA	T114,T123	C0035696
27858503	89	98	signature	T169	C1704864
27858503	142	155	breast cancer	T191	C0678222
27858503	156	164	patients	T101	C0030705
27858503	165	187	Extracellular vesicles	T026	C3894683
27858503	189	192	EVs	T026	C3894683
27858503	218	221	RNA	T114	C0035668
27858503	258	272	non-coding RNA	T114	C0887909
27858503	298	314	characterization	T052	C1880022
27858503	322	348	protein coding transcripts	T114	C1519595
27858503	352	355	EVs	T026	C3894683
27858503	387	401	RNA-Sequencing	T062	C1328904
27858503	403	410	RNA-Seq	T062	C1328904
27858503	417	431	EV populations	T026	C3894683
27858503	467	478	transcripts	T114	C1519595
27858503	489	498	expressed	T045	C1515670
27858503	542	551	oncosomes	T026	C0243092
27858503	556	564	exosomes	T026	C2350332
27858503	606	615	functions	T043	C0007613
27858503	634	648	EV populations	T026	C3894683
27858503	668	672	mRNA	T114,T123	C0035696
27858503	673	682	signature	T169	C1704864
27858503	712	723	donor cells	T025	C0007634
27858503	755	760	mRNAs	T114,T123	C0035696
27858503	770	797	E2F transcriptional targets	T116,T123	C0146462
27858503	802	818	histone proteins	T116,T123	C0019652
27858503	826	831	mRNAs	T114,T123	C0035696
27858503	846	855	expressed	T045	C1515670
27858503	863	870	S-phase	T079	C0080129
27858503	878	888	cell cycle	T043	C0007586
27858503	932	935	EVs	T026	C3894683
27858503	943	950	S-phase	T079	C0080129
27858503	952	961	In silico	T066	C3489666
27858503	962	970	analysis	T062	C0936012
27858503	977	1000	subcellular compartment	T026	C0729605
27858503	1001	1014	transcriptome	T086	C3178810
27858503	1015	1019	data	T078	C1511726
27858503	1029	1035	ENCODE	T170	C0282574
27858503	1036	1045	cell line	T025	C0007600
27858503	1071	1073	EV	T026	C3894683
27858503	1074	1079	mRNAs	T114,T123	C0035696
27858503	1097	1117	cytoplasmic RNA pool	T114	C2827481
27858503	1123	1125	EV	T026	C3894683
27858503	1126	1135	signature	T169	C1704864
27858503	1168	1174	plasma	T031	C0032105
27858503	1178	1186	patients	T101	C0030705
27858503	1192	1205	breast cancer	T191	C0678222
27858503	1209	1216	RNA-Seq	T062	C1328904
27858503	1239	1250	transcripts	T114	C1519595
27858503	1266	1275	expressed	T045	C1515670
27858503	1279	1282	EVs	T026	C3894683
27858503	1288	1296	patients	T101	C0030705
27858503	1335	1345	expression	T045	C1515670
27858503	1354	1360	normal	T023	C0444070
27858503	1365	1386	breast cancer tissues	T023	C0444070
27858503	1413	1438	high-throughput profiling	T063	C2936623
27858503	1442	1444	EV	T026	C3894683
27858503	1445	1449	mRNA	T114,T123	C0035696
27858503	1468	1471	EVs	T026	C3894683
27858503	1478	1504	tumor-specific alterations	T045	C0026882
27858503	1544	1564	cancer-derived cargo	T044	C1519628